BrightHeart, a Paris-based health technology company specializing in artificial intelligence for prenatal ultrasound, has secured $12.8 million in Series A financing to accelerate its international expansion. The round reflects growing investor confidence in AI-driven medical imaging, particularly in highly specialized and regulated clinical domains. With this funding, BrightHeart aims to broaden access to expert-level prenatal screening and improve early detection of congenital conditions worldwide.
A Strong Investor Consortium
The Series A round was co-led by Odyssée Venture and GO Capital, two firms known for backing scalable healthcare and impact-driven technologies. Additional participants included the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels, and existing investor Sofinnova Partners, alongside several clinicians and medtech entrepreneurs. The diversity of this investor group highlights both the clinical relevance and commercial potential of BrightHeart’s platform.
Scaling an AI Platform for Prenatal Care
BrightHeart plans to use the new capital to support commercialization in the United States, strengthen its presence across Europe, and continue product development. Its B-Right AI Platform is designed to deliver expert-level support during prenatal ultrasound exams, particularly for complex organs such as the fetal heart. By integrating directly into existing clinical workflows, the platform aims to enhance diagnostic accuracy without adding operational burden for healthcare professionals.
Addressing a Critical Clinical Challenge
Congenital heart defects remain among the most common and challenging conditions to detect during pregnancy. BrightHeart’s technology assists obstetricians and gynecologists by guiding image acquisition, ensuring exam completeness, and supporting real-time decision-making. This approach is intended to reduce variability in screening quality and bring specialist-level insights into routine prenatal care settings.
Regulatory and Clinical Momentum
The financing follows a year of significant progress for BrightHeart, marked by multiple regulatory and scientific milestones. In 2025, the company obtained five clearances from the U.S. Food and Drug Administration and established collaborations with leading academic medical centers. It also published two peer-reviewed clinical studies, positioning BrightHeart as the only company in its field with such validated evidence.
Positioning for Global Growth
With a growing regulatory footprint and increasing demand for AI-enabled diagnostics, BrightHeart is positioning itself as a reference platform in prenatal imaging. The company’s leadership believes the combination of clinical validation, workflow integration, and scalability will support adoption across diverse healthcare systems. This foundation is expected to facilitate global deployment while maintaining high standards of care.
Investor Perspectives
Investors emphasized the strength of BrightHeart’s clinical strategy and its focus on real-world usability. Representatives from Odyssée Venture highlighted the company’s robust evidence base in one of the most complex areas of medical imaging. GO Capital noted that the platform’s ability to pair advanced screening with operational efficiency could make it a standard tool in prenatal ultrasound.
Impact on Congenital Heart Defect Outcomes
The participation of the Mussallem CHD Alliance underscores the broader mission behind BrightHeart’s technology. The organization views early and accurate diagnosis as a key lever for improving outcomes for babies born with congenital heart defects. By embedding AI directly into routine ultrasound exams, BrightHeart is seen as helping close critical gaps in access to high-quality screening.
BrightHeart’s $12.8 million Series A marks a significant step in the evolution of AI-supported prenatal care. Backed by a strong consortium of healthcare-focused investors, the company is poised to expand its reach and further validate its technology on a global scale. As adoption grows, BrightHeart aims to redefine standards in prenatal ultrasound and contribute to better outcomes for families and clinicians alike.